{"id":913787,"date":"2026-10-02T19:08:12","date_gmt":"2026-10-02T19:08:12","guid":{"rendered":"https:\/\/www.newsbeep.com\/au\/913787\/"},"modified":"2026-10-02T19:08:12","modified_gmt":"2026-10-02T19:08:12","slug":"glp-1-weight-loss-drugs-keep-getting-cheaper-thank-competition","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/au\/913787\/","title":{"rendered":"GLP-1 Weight-Loss Drugs Keep Getting Cheaper: Thank Competition"},"content":{"rendered":"

Thirty years ago<\/a>, a small startup team of scientists in Boston published findings that began with the venom of a Gila monster and ended in a weight-loss revolution.\u00a0<\/p>\n

The breakthrough discovery \u2014 glucagon-like peptide compounds (GLP-1s) showed promise as a treatment for diabetes and obesity \u2014 was largely ignored<\/a>. Pfizer pulled the researchers\u2019 funding<\/a> and sold off<\/a> the license. Discovery doesn\u2019t guarantee medical progress \u2014 or market success.<\/p>\n

Not until 2021 did Novo Nordisk introduce Wegovy<\/a>, touching off a GLP-1 boom<\/a>. According to Gallup<\/a>, 11 percent of US adults now report taking a GLP-1 medication for weight loss: a quadrupling over the past two years.\u00a0<\/p>\n

John Puri at National Review<\/a> credits capitalism and innovation for transforming this scientific breakthrough into greater abundance. Coverage by insurers remains limited \u2014 and cash prices have fallen around 75 percent since 2021.<\/p>\n

When Wegovy\u2019s one-of-a-kind treatment debuted in 2021, a month\u2019s supply cost $1,349. At the time, blue-collar employees were earning an average of $26.12<\/a> an hour, putting the time-price at 51.65 hours per month, or more than six days\u2019 wages.\u00a0<\/p>\n

Employer insurance plans balked, and the government\u2019s health programs were barred from covering weight-loss drugs unless there was a specified medical complication. More than half<\/a> of American adults (137 million) meet the medical criteria to benefit from the FDA\u2019s approved uses of GLP-1s: the cost of covering them all is enormous.\u00a0<\/p>\n

Even with mostly cash payers, demand outstripped supply, putting Wegovy on the FDA\u2019s drug-shortage list<\/a>. With that designation came a legal path for pharmacies to compound the product themselves, and offer lower-priced alternatives through telehealth and cash-pay programs.\u00a0<\/p>\n

Two years later, a second major company gained FDA approval for an injectable drug for chronic weight management. Eli Lilly\u2019s Zepbound is pharmacologically different<\/a>, but its effects are similar and it competes for the same patients and insurer budgets. The list price undercut Wegovy, at $1,060.\u00a0<\/p>\n

Here\u2019s where things really get interesting.\u00a0<\/p>\n

Competition for Cash Patients Crashes Prices <\/p>\n

Eli Lilly knew few of the potential beneficiaries of its medication would qualify for the medication through their insurers. So it offered a special $550 cash price for patients whose insurance didn\u2019t cover GLP-1s. In 2024, it launched LillyDirect: a direct-to-consumer, cash-pay distribution for its competing product. Direct-to-consumer cash-pay pathways allowed patients to bypass asking \u201cwhich drug does my insurance cover?\u201d and forced manufacturers to compete in a more retail-like environment.<\/p>\n

And compete they did. Novo Nordisk introduced its own cash-pay option for Wegovy \u2014 NovoCare. Its lowest dose was priced at $499\/month. In April 2025, with the FDA\u2019s shortage resolved and still facing innumerable gray-market and privately compounded copies of semaglutide, Wegovy\u2019s price was reduced again, to make the authentic brand more price-competitive for patients, who Novo knew could easily switch. Standard self-pay injectable Wegovy dropped<\/a> to $349\/month, with a $199\/month introductory offer.<\/p>\n

In response, Eli Lilly cut Zepbound\u2019s cash pricing<\/a>, offering the typical maintenance dose for $299 by December 2025. Prescribers and patients became more comfortable switching<\/a> between major branded therapies<\/a> that filled essentially the same medical need. That increased the price pressure on drugmakers who were accustomed to negotiating with insurer formularies and formal rebate systems.<\/p>\n

Almost immediately after Zepbound\u2019s price reduction, the FDA approved<\/a> an oral formulation of Wegovy. Clinical trials show the once-a-day pill is almost as effective<\/a> as the injectable, and the pill form expands the available market to include patients unwilling to self-inject GLP-1s.\u00a0<\/p>\n

Today, the oral maintenance dose of brand-name Wegovy costs $299 a month for self-paying patients. Self-pay pricing for injectable Wegovy settled at $349. Fifty percent of sales of both Wegovy and Zepbound<\/a> are direct exchanges with cash-paying patients.\u00a0<\/p>\n

Our \u201caverage\u201d blue-collar worker from 2021 is now earning $32.53\/hour<\/a>. The time price of his monthly weight-loss treatment has fallen by 75 to 80 percent.\u00a0<\/p>\n

Over the same period, according to BLS reports, hospital services have risen 26.6 percent<\/a>, and medical care prices, 12.9 percent. Overall consumer inflation (CPI<\/a>) has increased 22.5 percent.<\/p>\n

The official monthly list price for Wegovy remains $1,349 per month in 2026, unchanged from its launch baseline.\u00a0<\/p>\n

\"\"<\/a><\/p>\n

So Does Wegovy Cost $1,349 or $299?\u00a0<\/p>\n

That vast discrepancy between \u201cofficial\u201d pricing for pharmacies and commercial insurers and the cash-pay price tells us an interesting story about how competition lowers price \u2014 and what gets in the way.<\/p>\n

Traditional health insurers have been hesitant to cover these expensive drugs for \u201ccosmetic\u201d weight loss, even as evidence of their effectiveness mounts. Fewer than one in five employers with 200 or more workers cover GLP-1s for obesity<\/a>, citing long-term use and high costs. As the drugs\u2019 popularity has exploded, the number of companies<\/a> that are willing<\/a> or can afford<\/a> to cover them is likely to decline<\/a>. Federal law prohibits Medicare Part D<\/a> from paying for weight-loss prescriptions in the absence of a comorbidity like diabetes, and just one percent<\/a> of individual Marketplace plans include access to GLP-1s.\u00a0\u00a0<\/p>\n

With insurers and bureaucrats out of the way, GLP-1 makers are pricing directly for their end customers. That\u2019s unusual for medical care, where insurers and government pay the bill and patients are insulated from the actual costs<\/a>.\u00a0<\/p>\n

Economists call this the third-party payer problem. When end users of medical care are paying with someone else\u2019s money, they have little incentive to shop around<\/a>. Doctors and drugmakers who can only access patients in need if their treatments are \u201ccovered\u201d end up viewing the bureaucrats as their customers.\u00a0<\/p>\n

Milton Friedman explained that under this \u201cbureaucratization of medical care\u201d the \u201ccaregiver has become, in effect, an employee of the insurance company or, in the case of Medicare and Medicaid, of the government.\u201d What\u2019s best for the patient becomes secondary, and \u201cis often in direct conflict with the interest of the caregiver\u2019s ultimate employer,\u201d the insurer.\u00a0<\/p>\n

Falling GLP-1 prices offer a glimpse of what\u2019s possible when third-party payers get out of the way. Competition gives consumers more choices. Competing brands have to adjust prices because they aren\u2019t selling to insurers or the government, but to the end-user, spending her own money.<\/p>\n

How \u201cFree\u201d Coverage Costs You More<\/p>\n

Just because competition is bringing prices down doesn\u2019t mean government will stay out of the market. Thirteen states<\/a> now cover GLP-1s through their Medicaid programs, with the federal taxpayers ultimately matching the tab<\/a>.\u00a0<\/p>\n

Medicare has gone further. In July 2026, CMS launched the Medicare GLP-1 Bridge<\/a> to give eligible Part D beneficiaries access to Wegovy<\/a> and a few competing GLP-1 drugs. CMS itself says the program sits outside ordinary Part D. Patients pay a $50 monthly copay, but participating manufacturers promised to provide<\/a> the program drugs at a net price of $245 per monthly supply.\u00a0<\/p>\n

CMS has negotiated a small discount (CMS\u2019s $245 net price is lower than the $299 retail cash price), but most of the cost has not disappeared; it has been shifted away from the person choosing the drug. The subsidy-and-copay model weakens the direct pricing mechanism that helped reduce cash prices in the first place. The user no longer confronts actual prices; taxpayers absorb much of the difference.<\/p>\n

Breaking the direct-pricing function for temporary savings demonstrates what John Puri<\/a> called the government\u2019s \u201cappetite for providing short-term relief at long-term expense.\u201d<\/p>\n

Unhappy Losers<\/p>\n

Not everyone is celebrating our shrinking appetites. Creating new value in markets is often accompanied by destroying<\/a> or displacing<\/a> existing value. When consumer behavior changes<\/a> as drastically as it has since the debut of GLP-1s, other industries<\/a> will be forced to adapt<\/a>. Welcome to the world of tradeoffs.<\/p>\n

Food Dive reports<\/a> that the increased adoption of GLP-1 drugs could \u201cput $73 billion in brand value at risk.\u201d If sales of appetite-suppressing medications soar, demand for calorie-dense snacks will drop. A Cornell study<\/a> found one household member taking GLP-1s reduced family grocery spending 6 percent<\/a>. Food giants like Doritos, Hershey\u2019s, Cheetos, Kellogg\u2019s and Reese\u2019s are particularly vulnerable. By one analysis, an estimated 45 percent of Frito-Lay\u2019s brand value is \u201cat structural risk to the medications.\u201d<\/p>\n

It\u2019s not just the snack aisle that\u2019s feeling the pressure. GLP-1 drugs are also changing America\u2019s drinking habits<\/a>.<\/p>\n

Ernst & Young reports<\/a> that 44 percent of GLP-1 users cut back on beer, wine, and liquor after beginning treatment. Even after stopping treatment, 82 percent maintained their healthier (and less-spendy) habits.<\/p>\n

Another big loser? Weight Watchers. The purveyors of traditional points-based dieting saw a cratering of demand<\/a> after injectable GLP-1s became widely available. The company accumulated $1.1 billion in debt, lost a million members and 40 percent of its stock value, and filed for Chapter 11<\/a> bankruptcy.\u00a0<\/p>\n

That\u2019s classic creative destruction<\/a>. The same innovation that makes weight loss more affordable could make life considerably more difficult<\/a> for companies selling potato chips, chocolate, and wine, as well as other families of weight-loss treatment. We\u2019re still learning what GLP-1s can do<\/a>: they soon could be disrupting businesses built on nicotine<\/a>, gambling<\/a>, drug<\/a> and alcohol<\/a> rehab, bariatric surgeries<\/a>, and even Alzheimer\u2019s care<\/a>.<\/p>\n

But prosperity is not measured by how much consumers must spend to get what they want. Innovation makes us all richer<\/a> when it lets us accomplish more<\/a> with fewer resources \u2014 even when doing so destroys the value of yesterday\u2019s products and business models. And GLP-1s are making successful weight loss far more abundant, at ever-lower cost.<\/p>\n","protected":false},"excerpt":{"rendered":"Thirty years ago, a small startup team of scientists in Boston published findings that began with the venom…\n","protected":false},"author":2,"featured_media":913788,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[33],"tags":[64,63,137,490],"class_list":["post-913787","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-au","tag-australia","tag-health","tag-medication"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/913787","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/comments?post=913787"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/913787\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media\/913788"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media?parent=913787"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/categories?post=913787"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/tags?post=913787"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}